Synthesis of enterovirus positive-strand RNAs: discovery of viral and host determinants of RNP complex formation

肠道病毒正链RNA的合成:RNP复合物形成的病毒和宿主决定因素的发现

基本信息

  • 批准号:
    9904920
  • 负责人:
  • 金额:
    $ 24.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-01-30 至 2021-12-31
  • 项目状态:
    已结题

项目摘要

Members of the Enterovirus genus of picornaviruses are responsible for a wide range of diseases, including myocarditis, paralytic poliomyelitis, the common cold, and encephalitis. In the cytoplasm of infected cells, these viruses (e.g., coxsackievirus, poliovirus, EV71, human rhinovirus) replicate their positive-sense RNA genome via a two-step process. First, the positive-sense genomic RNA is used as a template to synthesize a complementary negative RNA strand. This intermediate negative RNA strand then serves as a template to make multiple positive RNA strands that function both as mRNA and as genomic RNAs for new virus particles. To date, most studies of enterovirus RNA replication have focused on the first step: synthesis of the negative-strand RNA. Experiments proposed in this application will focus on the second, and arguably more central, step: synthesis of the multiple positive RNA strands needed to form new virus particles. Specifically, these studies will focus on a predicted RNA cloverleaf-like structure that forms at the 3’ end of the negative strand, the so-called 3’-cloverleaf (3’-CL). The 3’-CL is thought to form a platform that serves as a crucial player and binding site for different virus and host proteins that together initiate the 2nd RNA replication step. The first aim of the proposal will implement state-of- the-art approaches such as ChIRP-MS and RNA affinity methods coupled with mass spectrometry to identify host and virus proteins that interact with the 3’-CL of coxsackievirus B3 (CVB3). For the second aim, the three- dimensional structure of the predicted 3’-CL of CVB3 RNA will be solved, providing the first high resolution image of this critical replication platform. This will be done via a state-of-the-art combined NMR/Small Angle X-ray Scattering (SAXS) approach. In the final aim, CLIP-seq analysis and NMR-based chemical shift perturbation will be used to map the binding of the identified proteins onto the 3’-CL RNA structure. These studies will significantly advance our understanding of the key 2nd step of enterovirus RNA replication and identify novel therapeutic targets that may provide multiple opportunities to combat enterovirus infections by blocking the assembly of viral RNA replication complexes.
picornaviruses肠病毒属的成员负责各种疾病,包括 心肌炎,麻痹性脊髓灰质炎,普通感冒和脑炎。在感染细胞的细胞质中,这些 病毒(例如Coxsackievirus,Poliovirus,EV71,人类鼻病毒)通过通过 一个两步的过程。首先,阳性基因组RNA用作合成完整性的模板 负RNA链。然后,此中间负RNA链充当模板以使多个阳性 新病毒颗粒的RNA链作为mRNA和基因组RNA。迄今为止,大多数研究 肠病毒RNA复制的重点是第一步:负链RNA的合成。实验 在本应用程序中提出的将重点关注第二个,可以说是更中心的步骤:综合倍数 形成新病毒颗粒所需的正RNA链。具体而言,这些研究将集中于预测 在负链的3'末端形成的RNA三叶草状结构,即所谓的3'-Cloverleaf(3'-Cl)。 人们认为3'-CL形成了一个平台,该平台是不同病毒和宿主的关键参与者和具有约束力的站点 共同启动第二个RNA复制步骤的蛋白质。该提案的第一个目标将实施 ART方法,例如Chirp-Ms和RNA亲和力方法,结合质谱法以识别 与Coxsackievivirus B3(CVB3)相互作用的宿主和病毒蛋白。为了第二个目标,三 将求解预测的3'-CL CVB3 RNA的尺寸结构,提供第一个高分辨率图像 这个关键的复制平台。这将通过最先进的NMR/小角度X射线来完成 散射(SAXS)方法。在最终目的中,剪辑序列分析和基于NMR的化学移动扰动将 用于将鉴定蛋白的结合映射到3'-CL RNA结构上。这些研究将大大 促进我们对肠病毒RNA复制的关键第二步的理解并确定新疗法 可以通过阻止病毒的组装来打击肠内病毒感染的多种机会来打击肠病毒感染的目标 RNA复制复合物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Steven Pascal的其他基金

Synthesis of enterovirus positive-strand RNAs: discovery of viral and host determinants of RNP complex formation
肠道病毒正链RNA的合成:RNP复合物形成的病毒和宿主决定因素的发现
  • 批准号:
    10092097
    10092097
  • 财政年份:
    2020
  • 资助金额:
    $ 24.32万
    $ 24.32万
  • 项目类别:

相似海外基金

Emerging mechanisms of viral gene regulation from battles between host and SARS-CoV-2
宿主与 SARS-CoV-2 之间的战斗中病毒基因调控的新机制
  • 批准号:
    10725416
    10725416
  • 财政年份:
    2023
  • 资助金额:
    $ 24.32万
    $ 24.32万
  • 项目类别:
Targeting HNF4-induced thrombo-inflammation in Chagas disease
针对恰加斯病中 HNF4 诱导的血栓炎症
  • 批准号:
    10727268
    10727268
  • 财政年份:
    2023
  • 资助金额:
    $ 24.32万
    $ 24.32万
  • 项目类别:
LINE1-ORF0 in SLE pathogenesis
SLE 发病机制中的 LINE1-ORF0
  • 批准号:
    10681876
    10681876
  • 财政年份:
    2023
  • 资助金额:
    $ 24.32万
    $ 24.32万
  • 项目类别:
Glia Exclusive Gene Therapy
胶质细胞独家基因疗法
  • 批准号:
    10739502
    10739502
  • 财政年份:
    2023
  • 资助金额:
    $ 24.32万
    $ 24.32万
  • 项目类别:
Optimization of CRISPR genome editor and its delivery strategy for C9orf72 frontotemporal dementia
C9orf72额颞叶痴呆的CRISPR基因组编辑器优化及其递送策略
  • 批准号:
    10746565
    10746565
  • 财政年份:
    2023
  • 资助金额:
    $ 24.32万
    $ 24.32万
  • 项目类别: